Who
Seshadri Neervannan
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Tarsus Pharmaceuticals.
In numbers
- Trades disclosed
- 56
- Buys
- 0
- Sells
- 16
- Bought
- $0
- Sold
- $4.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 7 Jan 2021
- Last trade
- 4 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Sep 2026filed 9 Sep 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $388K4,564 at $85.00 | filing |
| 4 Sep 2026filed 9 Sep 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $388K4,564 at $85.00 | filing |
| 20 Mar 2026filed 24 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $200K2,989 at $66.75 | filing |
| 20 Mar 2026filed 24 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $200K2,989 at $66.75 | filing |
| 19 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $307K4,589 at $67.00 | filing |
| 19 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $307K4,589 at $67.00 | filing |
| 18 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $248K3,610 at $68.71 | filing |
| 18 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $248K3,610 at $68.71 | filing |
| 17 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $217K3,125 at $69.42 | filing |
| 17 Mar 2026filed 19 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $217K3,125 at $69.42 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —26,287 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,097 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,148 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,097 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,148 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,020 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,022 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,020 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,022 at $0.00 | filing |
| 15 Mar 2026filed 17 Mar 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —26,287 | filing |
News
No headline names them, or the companies they trade most, lately.